In this regard, a clinical trial performed on COVID-19 patients indicated the ability of a nanomicellar form of CUR to significantly decrease the mRNA expression and cytokine secretion levels of IL-6 and IL-1β [140], which may ameliorate disease's clinical manifestation and promote overall recovery. This evidence concerns the gene IL1B and COVID-19.